RxDoctor Payments Data

Angelika Snyder, DO

Family Medicine · Amherst, NYNPI 1861766859

Payments from drug & device makers

$544in general payments, 2019–2025

Across 19 payments — averaging $28.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$152
  • Okami Medical, Inc.$120
  • GSK$46
  • Lilly USA, LLC$40
  • Astellas Pharma US Inc$32
  • Pfizer$29
  • plus $126 from 7 others

What the payments were for

  • Food & beverage$544100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$544 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$16,980
Medicare patients
81
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$50,191
EliquisApixaban22$30,027
TrulicityDulaglutide11$28,274
MounjaroTirzepatide18$24,858
OzempicSemaglutide15$21,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,647
Levothyroxine Sodium196$4,190
Rosuvastatin Calcium227$3,810
Atorvastatin Calcium141$2,726
SynthroidLevothyroxine Sodium36$2,588
Metoprolol Succinate103$2,449
Gabapentin88$2,330
Valsartan55$2,022
Amlodipine Besylate182$1,790
Omeprazole138$1,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro$40$54,80343 claims
PfizerEliquis$29$30,02722 claims
Novo NordiskOzempic$24$21,17615 claims
GSKTrelegy Ellipta$46$18,64720 claims
AbbVieSynthroid$152$2,58836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →